Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [31] Comparison of anti hypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy
    Stergiou, GS
    Makris, T
    Papavasiliou, M
    Efstathiou, S
    Manolis, A
    JOURNAL OF HYPERTENSION, 2005, 23 (04) : 883 - 889
  • [33] Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy
    Yang, Y
    Ohta, K
    Shimizu, M
    Nakai, A
    Kasahara, Y
    Yachie, A
    Koizumi, S
    CLINICAL NEPHROLOGY, 2005, 64 (01) : 35 - 40
  • [34] Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload
    Tokioka-Akagi, T
    Fujimori, A
    Shibasaki, M
    Inagaki, O
    Yanagisawa, I
    JAPANESE JOURNAL OF PHARMACOLOGY, 2001, 86 (01) : 79 - 85
  • [35] Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients
    Kim, Yong Hoon
    Her, Ae-Young
    Rha, Seung-Woon
    Choi, Byoung Geol
    Choi, Se Yeon
    Byun, Jae Kyeong
    Kang, Dong Oh
    Jang, Won Young
    Kim, Woohyeun
    Baek, Ju Yeol
    Choi, Woong Gil
    Kang, Tae Soo
    Ahn, Jihun
    Park, Sang-Ho
    Park, Sung Hun
    Hong, Ji Yeon
    Park, Ji Young
    Lee, Min-Ho
    Choi, Cheol Ung
    Park, Chang Gyu
    Seo, Hong Seog
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2020, 19 (01) : 405 - 413
  • [36] Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients
    Yong Hoon Kim
    Ae-Young Her
    Seung-Woon Rha
    Byoung Geol Choi
    Se Yeon Choi
    Jae Kyeong Byun
    Dong Oh Kang
    Won Young Jang
    Woohyeun Kim
    Ju Yeol Baek
    Woong Gil Choi
    Tae Soo Kang
    Jihun Ahn
    Sang-Ho Park
    Sung Hun Park
    Ji Yeon Hong
    Ji Young Park
    Min-Ho Lee
    Cheol Ung Choi
    Chang Gyu Park
    Hong Seog Seo
    Journal of Diabetes & Metabolic Disorders, 2020, 19 : 405 - 413
  • [37] Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    Liu, Chia-Lin
    Shau, Wen-Yi
    Chang, Chia-Hsuin
    Wu, Chi-Shin
    Lai, Mei-Shu
    JOURNAL OF EPIDEMIOLOGY, 2013, 23 (05) : 344 - 350
  • [38] Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China
    Lyu, Si-Qi
    Yang, Yan-Min
    Zhu, Jun
    Wang, Juan
    Wu, Shuang
    Ren, Jia-Meng
    Zhang, Han
    Shao, Xing-Hui
    JOURNAL OF GERIATRIC CARDIOLOGY, 2020, 17 (12) : 750 - 758
  • [39] Role of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias
    Makkar, Kathy M.
    Sanoski, Cynthia A.
    Spinler, Sarah A.
    PHARMACOTHERAPY, 2009, 29 (01): : 31 - 48
  • [40] TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells
    Kyuden, Y
    Ito, T
    Masaki, T
    Yorioka, N
    Kohno, N
    PERITONEAL DIALYSIS INTERNATIONAL, 2005, 25 (05): : 483 - 491